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The complement system, consisting of >30 
proteins  in  plasma  and  on  the  cell  surface, 
plays roles in immunological responses, such 
as  opsonization  of  pathogens,  chemotaxis, 
and activation of leukocytes, direct killing of   
pathogens, bridging innate and adaptive im-
munity, and clearance of immune complexes 
and apoptotic cells (Brown, 1991; Walport,   
2001a).  On  the  other  hand,  inappropriate   
activation of complement affects the patho-
genesis  of  inflammatory  diseases  (Walport, 
2001b). Once the complement system is acti-
vated, a chain of reactions involving proteol-
ysis and assembly occurs, resulting in cleavage 
of  the  third  complement  component  (C3). 
The cascade up to C3 cleavage is called the 
activation pathway. There are three activa-
tion pathways; the classical, the alternative, 
and the lectin pathways. In general, the clas-
sical pathway is activated by antibody–antigen 
complexes and the other two, the alternative 
and the lectin pathways, function in innate 
immune defense. Recent studies reveal that 
C1q recognizes various ligands besides antibody–
antigen complexes, resulting in the activation 
of  complement  by  innate  immune  system   
(Lu  et  al.,  2008).  The  alternative  pathway 
does not involve specific recognition mole-
cules and also functions to amplify C3 activa-
tion (amplification loop). The lectin pathway 
involves carbohydrate recognition by man-
nose-binding  lectin  (MBL)  and  ficolins,   
and the subsequent activation of associated   
enzymes,  MBL-associated  serine  proteases 
(MASPs; Fujita, 2002). Three distinct MASPs, 
MASP-1  (Matsushita  and  Fujita,  1992), 
MASP-2 (Thiel et al., 1997), and MASP-3 
(Dahl et al., 2001) have been identified in 
many  species  of  vertebrates.  MASP-1  and 
MASP-3 are produced by alternative splicing 
from a single MASP1/3 gene, with the result 
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The complement system is an essential component of innate immunity, participating in the 
pathogenesis of inflammatory diseases and in host defense. In the lectin complement 
pathway, mannose-binding lectin (MBL) and ficolins act as recognition molecules, and 
MBL-associated serine protease (MASP) is a key enzyme; MASP-2 is responsible for the 
lectin pathway activation. The function of other serine proteases (MASP-1 and MASP-3)  
is still obscure. In this study, we generated a MASP-1– and MASP-3–deficient mouse 
model (Masp1/3/) and found that no activation of the alternative pathway was observed 
in Masp1/3/ serum. Mass spectrometric analysis revealed that circulating complement 
factor D (Df) in Masp1/3/ mice is a zymogen (pro-Df) with the activation peptide QPRGR 
at its N terminus. These results suggested that Masp1/3/ mice failed to convert pro-Df  
to its active form, whereas it was generally accepted that the activation peptide of pro-Df 
is removed during its secretion and factor D constitutively exists in an active form in the 
circulation. Furthermore, recombinant MASP-1 converted pro-Df to the active form in 
vitro, although the activation mechanism of pro-Df by MASP-1 is still unclear. Thus, it  
is clear that MASP-1 is an essential protease of both the lectin and alternative  
complement pathways.
© 2010 Takahashi et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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The restoration of the alterative pathway in Masp1/3/ 
mice by an active form of factor D
Circulating C3 is spontaneously converted to a C3b-like 
product called C3(H2O) upon thioester hydrolysis. In the 
presence of complement factor B (Bf) and complement factor 
D (Df), C3(H2O) is able to form the primary C3 convertase 
C3(H2O)Bb, which triggers the initial step of the alternative 
pathway (Pangburn and Müller-Eberhard, 1983). To clarify 
the underlying mechanisms of the aforementioned results, Bf 
cleavage was investigated by Western blotting. When serum   
from wild-type C57BL/6 mice was incubated at 37°C for 1 h,   
a fragment called Ba was cleaved from Bf by limited proteol-
ysis (Fig. 2 A, lane 1). The Ba fragment was also found in   
serum from Mbl-null mice, in which both MBL-A and 
MBL-C are absent (Fig. 2 A, lane 3; Shi et al., 2004), and exog-
enous C3(H2O) enhanced Bf activation (Fig. 2 A, lane 2 and 4). 
No Ba fragment was detected in the following incubation   
of serum from Masp1/3/ mice (lane 5), and a faint band of 
Ba  fragment  was  detected  in  the  presence  of  exogenous 
C3(H2O) (Fig. 2 A, lane 6). Because Bf was cleaved by Df, 
the addition of purified human Df (active form) to Masp1/3/ 
mice sera and the following incubation resulted in the cleav-
age of Bf (Fig. 2 A, lane 7). A very low level of hemolytic   
activity against rabbit erythrocytes in the sera of Masp1/3/ 
mice was compensated by adding active Df (Fig. 2 B), and 
the low level of C3 deposition on immobilized zymosan   
using serum from Masp1/3/ mice was also restored by   
active Df (Fig. 2 C). These results suggest that Masp1/3/ 
mice carry an abnormality in the activation of Df.
Circulating Df in Masp1/3/ mice is a zymogen that retains 
activation peptide at the N terminus
To identify the cause of this abnormality in Masp1/3/ mice, 
we  first  determined  the  serum  concentration  of  Df  by   
that they have a common heavy chain and individual light 
chains  (protease  domain;  Dahl  et  al.,  2001).  Although 
MASP-1 cleaves C3, C2, factor XIII, and fibrinogen in   
vitro (Matsushita and Fujita, 1995; Matsushita et al., 2000; 
Hajela et al., 2002; Chen and Wallis, 2004; Krarup et al., 
2008), the physiological significance of these events is un-
clear. To identify the roles of MASP-1 in vivo, we gener-
ated a MASP-1–deficient mouse in which MASP-3 is also 
absent (Masp1/3/). Using Masp1/3/ mice, we have 
shown previously that MASP-1 triggers the lectin pathway 
by  promoting  activation  of  MASP-2  (Takahashi  et  al., 
2008). In the present study, we found no activation of the 
alternative pathway in Masp1/3/ mice and analyzed the 
underlying mechanisms.
RESULTS AND DISCUSSION
MASP-1– and MASP-3–deficient mice lack activation  
of the alternative complement pathway
To determine whether the alternative pathway is activated 
in  Masp1/3/,  mouse  sera  were  assayed  for  hemolytic   
activity against rabbit erythrocytes and for C3 deposition 
ability using zymosan-coated microwells. In the hemolytic 
assay, mice with a C4-deficient background (C4/) and 
Mg2+-EGTA–containing buffer were used to eliminate the 
effects  of  the  classical  and  lectin  pathways.  Surprisingly, 
both assays demonstrated that sera derived from Masp1/3/   
mice  had  no  ability  to  activate  the  alternative  pathway   
(Fig. 1). In contrast, mice deficient in MASP-2 and small 
MBL-associated protein (sMAP; a truncated MASP-2:Masp2/
sMap/; Takahashi et al., 1999; Iwaki et al., 2006) showed 
a  considerable  amount  of  hemolysis  and  C3  deposition, 
similar to the control mice. Therefore, these results indicate 
that MASP-1 and/or MASP-3 are involved in activation of 
the alternative pathway.
Figure 1.  Masp1/3/ mice show no ability to activate the alternative pathway. (A) Rabbit erythrocytes (2.5 × 106) were incubated for 1 h with 
mouse serum in GVB containing Mg2+-EGTA. Hemolysis was measured in a microplate reader at 405 nm. Two individual C4-deficient (C4/), MASP-1/-3, 
and C4 triple-knockout (M1/3/C4/) mice and MASP-2/sMAP and C4 triple-knockout (M2/C4/) mice were analyzed. (B) Sera from wild-type 
C57BL6 (WT), Masp1/3/ (M1/3/), and Masp2/sMap/ (M2/) mice diluted with GVB containing Mg2+-EGTA were incubated in zymosan-coated 
microwells for 1 h. Bound C3 was detected by fluorescein-conjugated anti–mouse C3 antibody. Values are presented as relative fluorescence units (RFUs). 
Data are presented as means ± SD of three individual mice for each strain. Data from one out of two (A) or three (B) independent experiments with simi-
lar results are shown.JEM VOL. 207, January 18, 2010  31
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those in wild-type mice (Fig. S1). These bands were converted 
to a single 26-kD band by treatment with N-glycosidase F,   
indicating that mouse Df is modified by N-glycosylation, as 
previously reported (Cook et al., 1987). The deglycosylated Df 
in Masp1/3/ serum was slightly larger than that in wild-type 
mouse (Fig. 3, A and C).
Df is thought to circulate in blood as an activated protease 
(Rosen et al., 1989). A putative activation peptide QPRGR 
predicted from its cDNA sequence is removed during Df 
maturation and secretion (Cook et al., 1985). Therefore, it is 
probable that Df in Masp1/3/ mice still retains the activa-
tion peptide. To verify this, we performed electrospray ion-
ization time-of-flight mass spectrometry (ESI-TOF-MS) of 
Df-derived fragments cleaved by V8 protease. As shown in 
Fig. 3 B, a molecular ion peak at 616.33 m/z ([M+H]+), cor-
responding to the mass of an N-terminal activated Df frag-
ment ILGGQE, was detected after cleavage of Df from 
wild-type, showing that wild-type mouse has an active Df. 
The internal amino acid sequence of the peptide in this peak 
was confirmed by tandem mass spectrometry analysis (Fig. S2 
and Table S1). Among V8 protease-treated fragments of Df 
from Masp1/3/ mice, however, a different molecular ion 
peak at 597.33 m/z ([M+2H]2+) was observed. The calcu-
lated mass (1,192.64) of the peptide responsible for this peak 
corresponded to the sequence (p)QPRGRILGGQE, includ-
ing a modified N-terminal pyroglutamate. The internal 
amino acid sequence in this peak was also confirmed by   
tandem mass spectrometry analysis (Fig. S2 and Table S1).
These results revealed that Masp1/3/ mice failed to 
convert pro-Df to its active form. Thus, it seems likely that 
MASP-1 and/or MASP-3 is involved in the cleavage of the 
activation peptide from pro-Df.
3T3-L1 cells that are differentiated into adipocytes  
secrete pro-Df
Adipose is the main tissue that produces Df, which is secreted 
into the peripheral blood (Cook et al., 1987; White et al., 
1992).  As  previously  reported  (Volanakis  and  Narayana, 
1996),  several  studies  have  revealed  that  the  activation 
peptide  of  pro-Df  is  removed  by  a  putative  trypsin-like   
protease during its secretion from adipocytes. On the other 
hand, pro-Df that was able to be activated by trypsin was   
observed in human serum (Fearon et al., 1974), suggesting 
that  pro-Df  secretes  from  human  adipocytes.  Masp1  and 
Masp3 mRNAs could not be detected in murine adipose   
tissue (Fig. S3). Therefore, it is probable that MASP-1 and/
or MASP-3 cleave pro-Df in the circulation after its secretion 
from adipocytes. We next determined whether pro-Df was 
cleaved in the circulation after its secretion from adipocytes 
using differentiated 3T3-L1 adipocytes. As shown in Fig. 3 C, 
the size of the deglycosylated Df in differentiated 3T3-L1   
adipocytes (lane 2) was larger than that in wild-type mouse 
serum (lane 3). Mass spectrometry analysis revealed that Df 
produced by differentiated 3T3-L1 adipocytes still retained 
the activation peptide, showing that pro-Df is activated after 
its secretion from adipocytes.
sandwich ELISA. The concentration of Df in Masp1/3/  
serum (26.9 ± 7.3 mg/l; n = 5) was not significantly different 
from that in C57BL/6 serum (32.2 ± 16.7 mg/l; n = 5). Next, 
to investigate the size and modifications of Df in Masp1/3/ 
serum,  circulating  Df  was  isolated  by  immunoprecipitation 
with a polyclonal anti–mouse Df antibody. Df was detected as 
40–44-kD broad bands that could not be distinguished from 
Figure 2.  Df restores the deficiency of alternative pathway activa-
tion in Masp1/3/ mice. (A) Immunoblot analysis of Bf incubated with 
the sera of wild-type C57BL/6 (WT), MBL-A, and -C double-deficient (Mbl 
null) and Masp1/3/ mice at 37°C for 30 min. Each serum type was incu-
bated with (+) or without () 1.25 µg C3(H2O). Serum from Masp1/3/ 
mice was also incubated with (+) human Df (0.2 µg). Note: an additional 
band (26 kD) was also detected with Ba, but it was not identified. (B) A  
hemolytic assay using rabbit erythrocytes was performed. Percent hemo-
lysis induced by sera (25 µl) from wild-type (WT), Masp1/3/ (M1/3/), 
and Masp1/3/ mice supplemented with 0.2 µg human Df (huDf) is indi-
cated. (C) A C3 deposition assay on immobilized zymosan was performed.  
5 µl of sera from wild-type (WT), Masp2/sMap/ (M2/), and 
Masp1/3/ (M1/3/) mice supplemented with 0.2 µg human Df  
(huDf) were analyzed. Data are presented as the means ± SD of three  
independent experiments.32 MASP-1 cleaves zymogen of factor D | Takahashi et al.
compared with reconstitutions without rMASP-1K (Fig. 4 C,   
lane 6). These results indicate that MASP-1 is able to directly 
activate pro-Df to Df, which in turn activates Bf in a Bf–CVF 
complex. This activated Bf can cleave C3 to initiate the am-
plification loop of the alternative pathway.
A  question  was  raised  as  to  why  rMASP-1K  did  not 
cleave endogenous pro-Df in serum of Masp1/3/ mouse, 
as shown in Fig. 4 B. Native MASP-1 in the circulation is 
thought to be a zymogen. However, the major portion of 
rMASP-1K  has  been  already  activated  during  expression   
and purification. Therefore, the question should be explained 
by previous studies (Matsushita et al., 2000; Petersen et al., 
2000; Rossi et al., 2001), which show that activated MASP-1 
is immediately neutralized by C1 esterase inhibitor and 
-2-macroglobrin.
WT serum could cleave pro-Df in Masp-1/3-deficient serum
To clarify the above question, we generated a rabbit antibody 
to recognize the activation peptide (QPRGR) of pro-Df. 
This  antibody  was  able  to  detect  pro-Df  in  serum  from 
Masp1/3/  mouse,  but  not  active  Df  in  that  from  WT 
mouse by two biochemical analyses (Fig. 5, A and B), show-
ing that pro-Df was not detected in normal mouse serum. 
Using this antibody, we asked whether WT serum that con-
tains endogenous MASP-1 has an ability to cleave endoge-
nous pro-Df in Masp1/3/ serum. When both sera were 
incubated together at 37°C, pro-Df that was captured by   
the specific antibody decreased in a time-dependent manner 
(Fig. 5 C). This result suggested that pro-Df in Masp1/3/ 
serum  is  converted  to  its  active-form  by  the  endogenous 
MASP-1. However, it is generally accepted that most MASP-1 
Recombinant MASP-1 cleaves and activates pro-Df
Recombinant  pro-Df  has  been  produced  in  insect  cells   
using a baculovirus expression system (Rosen et al., 1989; 
Yamauchi et al., 1994). We also prepared recombinant mouse 
pro-Df containing a hexahistidine (6xHis) tag using a baculo-
virus system. Our mass spectrometry analysis revealed that 
the recombinant Df produced by this system was pro-Df with 
the activation peptide (unpublished data). To assess whether 
recombinant pro-Df is a substrate for MASP-1, recombinant 
pro-Df was incubated with rMASP-1K, which was modified 
by replacing the arginine residue at the reactive site P1 for 
activation of MASP-1 with lysine (Takahashi et al., 2008). 
rMASP-1K  overcame  the  problem  of  self-activation  and 
degradation, allowing us to produce larger amounts of the 
recombinant protein. As shown in Fig. 4 A (lanes 2 and 4), 
rMASP-1K reduced the molecular weight of deglycosylated   
recombinant  pro-Df  to  that  of  active  Df,  indicating   
that MASP-1 is able to directly cleave the activation peptide   
in pro-Df.
Next, we elucidated whether the active Df generated by 
rMASP-1K can activate the alternative pathway. Incubation 
of recombinant pro-Df with rMASP-1K fully restored the 
C3 deposition activity of serum from Masp1/3/ mice on 
immobilized zymosan, while neither pro-Df nor rMASP-1K 
alone produced an effect (Fig. 4 B). Furthermore, we recon-
stituted the C3 convertase of the alternative pathway by 
mixing purified components, including cobra-venom factor 
(CVF),  Bf  and  recombinant  pro-Df.  CVF  is  a  structural   
homologue of C3b that forms a stable complex with Bf. As 
shown in Fig. 4 C, the incubation of recombinant pro-Df 
with rMASP-1K increased the cleavage of Bf (Fig. 4 C, lane 5), 
Figure 3.  Circulating Df in Masp1/3/ mice is a zymogen. (A) Endogeneous Df was immunoprecipitated and immunoblotted with a polyclonal 
anti-Df antibody. Precipitated Df was incubated with N-glycosidase F (Endo-F) to remove N-glycosylations. Sera from wild-type (WT) and Masp1/3/ 
mice were analyzed. (B) Endogenous Df was immunoprecipitated from the sera of wild-type (C57BL6; top) and Masp1/3/ mice (bottom). V8 protease-
digested fragments were analyzed by ESI-TOF-MS. The range from 590 to 630 (m/z) is presented. (C) Western blotting of Df in culture supernatants from 
undifferentiated 3T3-L1 cells (lane 1) and differentiated 3T3-L1 cells (lane 2) were analyzed. As a control, precipitated Df from the sera of wild-type  
(lane 3) and Masp1/3/ mice (lane 4) was used in immunoblotting experiments. Data from one out of three (A and C) or two (B) independent  
experiments with similar results are shown.JEM VOL. 207, January 18, 2010  33
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is circulating as a zymogen and activated through MBL   
and ficolins, although recombinant MASP-1 was easily auto-
activated (Rossi et al., 2001; Ambrus et al., 2003; Zundel   
et  al.,  2004).  Therefore,  it  is  speculated  that  endogenous   
zymogen  of  MASP-1  would  somehow  be  activated  and 
cleave pro-Df, even in presence of inhibitors. The situation is 
more complicated, because free unbound MASP-1 to MBL 
is circulated in plasma (Terai et al., 1997; Thiel et al., 2000), 
and the precise roles and activation mechanisms of the free 
MASP-1 are also not clear. The underlying mechanism for 
the role of free MASP-1 is currently under investigation.
Figure 4.  MASP-1 activates pro-Df. (A) Recombinant pro-Df (80 ng) 
was incubated with 120 ng (lane 2) and 240 ng (lane 4) of recombinant 
MASP-1 (rMASP-1K) at 37°C for 1 h. As a control, pro-Df was incubated 
without rMASP-1K (lanes 1 and 3). After removing N-glycosylations by  
N-glycosidase F treatment, samples were separated by SDS-PAGE and  
immunoblotted with anti-Df antibody. Data are representative of two 
independent experiments. (B) A C3 deposition assay on immobilized zy-
mosan was performed. 5 µl of the sera of wild-type (WT) and Masp1/3/ 
(M1/3/) mice supplemented with 0.2 µg of pro-Df alone (+pro-Df),  
0.03 µg of recombinant MASP-1K alone (+rM1K) or pro-Df (0.2 µg) that 
was preincubated with rMASP-1K (0.03 µg; +pro-Df+rM1K) are analyzed. 
Data are presented as the means ± SD of three independent experiments. 
(C) A reconstitution experiment using purified components, i.e., CVF, Bf, 
and recombinant pro-Df was performed. Samples were subjected to  
electrophoresis under nonreducing conditions and stained with Coomassie. 
Before reconstitution with CVF and Bf, pro-Df was preincubated with 
rMASP-1K (lane 4 and 5). Data are representative of two independent  
experiments.
Figure 5.  Specific detection of pro-Df and kinetic analysis for 
cleavage of its activation peptide. (A) Pro-Df was detected by a  
sandwich ELISA. Endogenous Df in mouse sera was captured in anti-Df 
antibody-coating wells, followed by detection of pro-Df with antibody 
specific for the activation peptide of mouse pro-Df. (B) Sera (0.5 µl) from 
WT (lane 1) and Masp1/3/ (lane 2) mice were analyzed by immunoblot-
ting using anti-Df (top) and anti–pro-Df (bottom) under reducing condi-
tions. (C) Masp1/3/ serum was incubated with same volume of WT 
serum at 37°C for 1 h (lane 2), 2 h (lane 3), and 3 h (lane 4). As controls, 
Masp1/3/ serum (lane 1) or WT serum (lane 5) was incubated for 3 h. 
Incubated samples corresponding to 0.5 µl of serum were immunoprecipi-
tated with anti–pro-Df, followed by treatment of N-glycosidase-F.  
Captured pro-Df was detected by immunoblot with anti-Df. (D) Kinetic 
analysis to cleave a fluorogenic synthetic substrate (H-QPRGR-MCA) by 
thrombin and rMASP-1K. Each enzyme (1 nM) was used to cleave 20 µM 
of substrate. (E) After MASP-1 was pulled down from the purified rMASP-
1K using anti–MASP-1 antibody (open circles) or the irrelevant antibody 
as control (filled circles), and the samples were used for cleavage of the 
synthetic substrate. All data represent one of similar results obtained 
from at least two experiments.34 MASP-1 cleaves zymogen of factor D | Takahashi et al.
using C2-deficient sera. Our findings suggest that the Df in 
such serum should be already activated by MASP-1, before 
the activation of C3 by the MBL-dependent C2 bypass on 
solid-phase polysaccharides.
Interestingly, increasing evidence suggests that the alter-
native pathway is involved in human disease, such as inflam-
matory arthritis and ischemia/reperfusion injury (Thurman 
and Holers, 2006). It was also reported that the alternative   
pathway is involved in fat metabolism in adipose tissue   
(Paglialunga et al., 2008). Recent studies have indicated that 
acylation-stimulating  protein  (ASP),  which  is  identical  to 
C3adesArg, stimulates fat storage in adipocytes (Yasruel et al., 
1991; Maslowska et al., 1997). ASP is a derivative of comple-
ment C3; thus, C3/ mice are lean owing to ASP deficiency 
(Murray et al., 2000). Furthermore, plasma ASP levels are 
decreased in Bf-deficient and Df-deficient mice, indicating 
that the alternative pathway stimulates production of ASP 
(Paglialunga et al., 2008). We found that Masp1/3/ mice   
are  also  apparently  lean  (Takahashi  et  al.,  2008),  strongly   
indicating a contribution of MASP-1 to fat metabolism via 
the alternative pathway activation.
In short, MASP-1, one of the enzymes in the lectin path-
way, also activates zymogen of Df in the alternative pathway 
and plays important roles in activation of both pathways.
MATERIALS AND METHODS
Mice. Wild-type mice, C57BL/6 (C57BL/6JJcl), were provided by CLEA 
Japan, Inc. Masp1/3/ (Masp1tm1Tefu) mice (Takahashi et al., 2008) and 
Masp2/sMap/ mice (Iwaki et al., 2006) have been described previously. 
C4/ (C4btm1Crr) (Wessels et al., 1995) mice were provided by The Jackson 
Laboratory. To generate mice with a C4/ background, Masp1/3/ mice 
were backcrossed with C4/ mice. Mice were used for experiments at 8–12 
wk of age. All animal protocols were approved by the Animal Care and Use 
Committee in accordance with the Guidelines for the Animal Experiments 
of Fukushima Medical University, Japanese Government Law Concerning 
the Protection and Control of Animals and Japanese Government Notifica-
tion on Feeding and Safekeeping of Animals.
Materials.  Purified  human  Df  and  C3  were  prepared  as  previously   
described (Fujita et al., 1981; Matsushita and Okada, 1986). The fluorogenic 
synthetic  substrate  H-Gln-Pro-Arg-Gly-Arg-4-methylcoumaryl-7-amide 
(H-QPRGR-MCA) was synthesized by GL Biochem. 7-Amido-4-methyl-
coumarin (AMC) and human thrombin were purchased from Sigma-Aldrich. 
Recombinant mouse MASP-1K was expressed and purified as previously 
described (Takahashi et al., 2008). Purity of rMASP-1K was estimated as 
17% in total protein by Western blotting against MASP-1 to compare the 
density of sequential dilution of rMASP-1K with that of quantified amount 
of  highly  purified  rMASP-1i  that  is  an  inactive  mutant  of  recombinant 
MASP-1 (Takahashi et al., 2008).
Assay  for  activation  of  the  alternative  pathway  on  immobilized   
zymosan. Black MaxiSorp microwells for measurement of fluorescence 
(Nunc) were coated with 0.1 ml of 20 µg/ml zymosan (Sigma-Aldrich) in 
0.1 M sodium carbonate buffer, pH 9.5, and incubated at 4°C overnight. 
Wells were blocked with 1% BSA in Tris-buffered saline (TBS) for 2 h at 
room temperature. After washing the wells four times with TBS containing 
0.05% Tween 20 (TBS-T), serum samples diluted in BBS buffer (0.2 M   
boric acid, 0.14 M NaCl, pH 8.0) with Mg2+-EGTA were added to each 
well and incubated for 1 h at 37°C. Wells were washed with TBS-T and 0.1 
ml of a 1/500 dilution of fluorescein-conjugated anti–mouse C3 IgG (Cappel) 
was added to each well and incubated for 30 min at room temperature. After 
Kinetic activity of rMASP-1K against H-QPRGR-MCA  
to compare with that of thrombin
Other serum proteases that are involved in the coagulation 
system, such as thrombin, kallikrein, and plasmin, were able 
to cleave pro-Df in vitro (Yamauchi et al., 1994). To assess 
the specific activity of MASP-1 for cleavage of pro-Df 
through kinetic analysis, we prepared a fluorogenic synthetic 
substrate (H-QPRGR-MCA) that is identical to the activa-
tion peptide of Df. Cleavage of the synthetic substrate by 
rMASP-1K  was  almost  twofold  faster  than  cleavage  by 
thrombin (Fig. 5 D). A substrate specificity constant, kcat/
Km of rMASP-1K (29.7 ± 5.9 M1 s1), against the synthetic 
substrate was almost twofold higher than that of thrombin 
(16.7 ± 6.7 M1 s1), although Km of MASP-1K (6.2 ± 0.5 mM)   
was higher than that of thrombin (1.0 ± 0.4 mM). Pro-Df 
was stably obtained from only MASP-1/3-deficient serum; 
nevertheless, the clotting of MASP-1/3–deficient blood   
occurred normally. This observation ruled out the possibility 
that these serum proteases that contribute to coagulation 
would be physiologically involved in the cleavage of pro-Df. 
In addition, this activity of MASP-1K to cleave the synthetic 
peptide almost vanished by pulling down with anti–MASP-1 
antibody (Fig. 5 E), indicating that rMASP-1K did not con-
tain any protease to nonspecifically cleave pro-Df.
Thus, we have found a novel function of MASP-1: it 
converts pro-Df into its active form in the circulation. We 
have previously demonstrated that MASP-1 contributes to 
the activation of the lectin pathway (Takahashi et al., 2008). 
To date, the three cascades leading to complement activation 
have been thought to be independently activated by distinct 
factors and to converge on the cleavage of C3. We report 
here that MASP-1 is the enzyme for complement activation 
that not only enhances the activation of MASP-2, but also 
activates  pro-Df.  Because  MASP-1  and  MASP-3  have  a 
common heavy chain, it is possible that MASP-3 is involved 
in the activation of pro-Df. Although the preliminary experi-
ments show that in addition to MASP-1, MASP-3 has an ac-
tivity to cleave pro-Df, further investigation will be necessary 
to determine whether some other factor affects the activation 
of pro-Df through cooperation with MASP-1 and MASP-3.
Another important finding is that Df is not secreted as   
the active form, in contrast to previous studies (Barnum and 
Volanakis, 1985; White et al., 1992). As shown in Fig. 3, we 
demonstrated that differentiated adipocytes secreted pro-Df 
with the activation peptides, clearly indicating that pro-Df is 
cleaved after secretion. In this respect, the results of the pres-
ent study clarify the role of MASPs in the MBL-dependent 
C2 bypass mechanism for alternative pathway-mediated C3 
activation reported by Selander et al. (Selander et al., 2006). 
They demonstrated that human C2-deficient serum could 
activate C3 on solid-phase bacterial polysaccharides, and this 
activation was dependent on MBL, but not on MASP-1, -2 
and -3. They discussed that bound MBL on solid-phase poly-
saccharides might provide a C3-binding site, resulting in the 
activation of the alternative pathway. In their study, three 
MASPs  were  depleted  from  serum  by  specific  antibodies   JEM VOL. 207, January 18, 2010  35
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was 50 µl). 5 µl of each sample was separated by SDS-PAGE under reducing 
conditions and transferred to PVDF membranes. Factor B was detected with 
a rabbit anti-serum against human factor B and peroxidase-conjugated   
secondary antibody, and visualized by chemiluminescence (ECL Plus; GE 
Healthcare) using a LAS3000 imaging system (Fuji Film).
Immunoprecipitation and immunoblotting. Mouse serum (diluted with 
TBS) or culture supernatant of differentiated 3T3-L1 adipocytes was incubated 
for 1 h at 4°C with affinity-purified rabbit anti-Df IgG (2.5 µg) and 10 µl of   
recombinant  protein  A-agarose  (GE  Healthcare).  Beads  were  washed  four   
times with TBS, and then denatured at 100°C for 5 min in 40 µl of TBS con-
taining 0.1% SDS and 50 mM -mercaptoethanol. Denatured samples were 
mixed with 2 µl of 10% Triton X-100 and 0.2 µl of N-glycosidase F (EMD) and 
incubated for 2 h at 37°C or overnight at room temperature. After centrifuga-
tion, 1–5 µl of supernatants was subjected to immunoblot analysis using bioti-
nylated affinity-purified rabbit anti-Df and peroxidase-conjugated Vectastain 
ABC kit (Vector Laboratories). Images were visualized by chemiluminescence.
Cleavage of Bf bound to cobra venom factor in vitro. Purified cobra 
venom factor (0.9 µg) was incubated overnight at 37°C with various combi-
nations of purified human factor B (1 µg), pro-Df (0.2 µg), and rMASP-1K 
(0.2 µg) in 10 µl of TBS containing 10 mM MgCl2 and 10 mM CaCl2. Sam-
ples were separated by SDS-PAGE under nonreducing conditions and gels 
were stained with Coomassie brilliant blue R-250.
Cell culture and differentiation of 3T3-L1 cells. The mouse 3T3-L1 cell 
line (JCRB9014) was obtained from the Health Science Research Resources 
Bank (HSRRB) in Japan. 3T3-L1 cells were cultured and differentiated into 
adipocytes using commercial media. In brief, at 2 d after confluence, cells were 
induced to differentiate with 3T3-L1 Differentiation Medium (Zen-Bio, Inc.) 
according to the manufacturer’s manual. After 3 d, the media were replaced 
with 3T3-L1 Adipocyte Maintenance Medium (Zen-Bio, Inc.). The cells 
were  subsequently  fed  every  3  d  with  Maintenance  Medium.  Cultured   
medium from 7–9 d after differentiation was collected to detect Df.
Mass spectrometry. Partial purification of mouse Df was performed by 
binding to a HiTrap NHS-activated HP column (GE Healthcare) coupled to 
anti-Df antibody. Eluted samples were separated by SDS-PAGE and stained. 
Bands  were  excised  and  digested  with  V8  protease  (Sigma-Aldrich).   
Extracted peptides were analyzed by QSTAR electrospray ionization time-
of-flight tandem MS (Applied Biosystems).
Enzyme assays. Thrombin or rMASP-1K was incubated in phosphate-
  buffered saline containing 0.05% Tween 20 and 0.1 mM bestatin in a total vol-
ume of 100 µl at 25°C, using as a substrate H-QPRGR-MCA (20–2,000 µM).   
Fluorescence was monitored with time at excitation and emission wave-
lengths of 360 and 465 nm using a DTX880 (Beckman Coulter). To obtain 
a standard curve, dilutions of AMC were prepared in the same assay buffer 
and corresponding fluorescence was measured. All enzyme kinetic parame-
ters were computed by fitting data to the Michaelis-Menten equation and 
determined from Lineweaver-Burk blot.
Statistical analysis. The statistical significance of differences was assessed 
by the Student’s t test. P values <0.05 were considered significant.
Online supplemental material. Fig. S1 shows immunoprecipitation and 
immunoblot of mouse Df from mouse sera. Fig. S2 shows tandem mass 
profiles from molecular ion peaks from V8-protease digested Df fragments 
of WT and Masp1/3/ mice. Fig. S3 shows expression of Df and Masp1 
in mouse adipose and liver tissue by RT-PCR. Table S1 shows summary of 
tandem mass profiles presented in Fig. S2. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20090633/DC1.
We thank K. Takahashi of Massachusetts General Hospital, Boston for kindly 
providing Mbl null sera.
washing four times with TBS-T and once with TBS, each well was filled 
with 0.1 ml of TBS. Fluorescence was measured using a DTX880 plate 
reader (Beckman Coulter; excitation at 485 nm and emission at 535 nm).
Hemolytic assay for the alternative complement pathway. Rabbit 
erythrocytes (2.5 × 106) were incubated at 39°C for 1 h with mouse serum 
diluted in gelatin-veronal buffer (GVB) containing 30 mM EGTA and 35 mM 
MgCl2  (Mg2+-EGTA;  0.1  ml  total  volume).  Heat-inactivated  (60°C  for   
10 min) serum was used as a control (0% lysis). After centrifugation, super-
natants (50 µl) were transferred to an ELISA plate. Hemolysis was measured 
in a DTX880 microplate reader at 405 nm. Percent hemolysis was calculated 
relative to complete lysis by water.
Expression and purification of mouse complement Df. Full-length 
mouse Df cDNA was amplified by RT-PCR using total RNA isolated from 
C57BL/6 adipose tissue with a high-fidelity polymerase (PrimeSTAR HS; 
Takara Bio Inc.) and the following primers: 5 primer (BamHI site in italics), 
5-TGCCGGATCCCAGAATGCACAGCTCCGT-3;  3  primer  (XbaI 
site in italics), 5-GGTGTCTCTAGAGGATGTCATGTTACCA-3. To 
add the sequence encoding the hexahistidine tag at 3-end of the cDNA in 
place of the native stop codon, a second PCR was performed using the pri-
mary amplification product as template, the same 5 primer, and another 3 
primer (XhoI site in italics), 5- ACTCGAGTCAATGGTGATGGTGAT-
GATGTCTAGATGTCATGTTACCATTT-3.  The  PCR  amplification 
product was cloned into the BamHI and XhoI sites in pBacPAK9 (Takara 
Bio Inc.). Recombinant baculovirus encoding mouse Df was produced by 
transfection of Sf21 insect cells with BacPAK6 viral DNA (Bsu36I digest; 
Takara Bio, Inc.) together with the aforementioned transfer plasmid.
The  recombinant  protein  was  isolated  from  serum-free  conditioned   
supernatant  of  Sf21  cells  infected  with  the  recombinant  baculovirus  by   
HisTrap (1 ml) column (GE Healthcare) and by gel filtration. Only single 
band was observed in rDf by SDS-PAGE and staining with CBB.
Preparation  of  antibodies  against  mouse  factor  Df. Monospecific   
antiserum recognizing mouse factor Df was raised by immunizing a rabbit 
with purified recombinant Df in CFA (Invitrogen), followed by two booster 
injections of the same antigen in IFA (Invitrogen) at 2-wk intervals. Antise-
rum was collected two weeks after the last immunization. Immunoglobulin 
was purified using HiTrap Protein G HP columns (GE Healthcare). Affinity 
purification  of  antibodies  against  mouse  Df  was  achieved  using  HiTrap 
NHS-activated HP columns (GE Healthcare) coupled to recombinant Df. 
Affinity-purified antibody (0.1 mg) was biotinylated using a Biotin Labeling 
kit-NH2 (Dojindo).
We  also  obtained  a  rabbit  polyclonal  antibody  that  recognizes  the   
activate peptide, “QPRGR” of mouse pro-Df (anti–pro-Df). In brief, rabbits   
were  immunized  with  keyhole  limpet  hemocyanin  (KLH)–conjugated   
15-mer peptide, “QPRGRILGGQEAAA.” After Igs were purified with 
this 15-mer peptide, the specific antibody that only recognizes the active 
peptide was obtained by passing twice through a column that was conjugated 
with a peptide, “ILGGQEAAA.”
ELISA. Df or pro-Df concentrations in murine sera were determined with 
newly established sandwich ELISA using recombinant Df as standard. The 
affinity-purified  antibodies  against  mouse  Df  were  coated  on  MaxiSorp 
ELISA plates (Nunc) at 0.5 µg/well in 0.1 M carbonate buffer pH 9.6 over-
night. After the plates were blocked with 1% BSA in PBS for 2h, diluted 
murine  sera  were  incubated  in  the  wells  for  30  min.  Captured  Df  was   
detected by biotinylated affinity-purified rabbit anti-Df or anti–pro-Df and 
peroxidase-conjugated Vectastain ABC kit (Vector Laboratories).
Bf activation in mouse serum. To make C3(H2O), purified human C3 
(0.25 mg/ml) was incubated at 37°C for 2 h in PBS containing 2 M potas-
sium bromide. After incubation, it was dialyzed in TBS twice. Mouse serum 
(10 µl) was incubated at 37°C for 30 min with or without 1.25 µg of 
C3(H2O) in TBS containing 5 mM MgCl2 and 5 mM CaCl2 (final volume 36 MASP-1 cleaves zymogen of factor D | Takahashi et al.
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